Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Kimberly Lee who wrote (40992)	1/8/1999 2:28:00 PM
From: Tokyo VD	Respond to of 119973

=EntreMed Up 15% After Endostatin Report In Medical Journal 1/8/99 14:23 By Otesa Middleton WASHINGTON (Dow Jones)--EntreMed Inc.'s (ENMD) stock shot up 15% Friday after the journal Cancer Research published a favorable article about its endostatin. EntreMed made instant headlines last year when it was widely reported that its endostatin may be a cancer cure because it killed tumors in mice. Soon after, however, the report researchers said the promising results couldn't be duplicated. The latest results, published in an abstract in the Jan. 1 edition of Cancer Research, said further research provides "formal proof" that endostatin stops tumor cell reproduction. EntreMed recently traded at 24, up 3 1/8, on volume of 455,900, compared with a daily average of 288,900. (MORE) DOW JONES NEWS 01-08-99 02:24 PM - - 02 24 PM EST 01-08-99